Hart, Daniel P.
Branchford, Brian R.
Hendry, Sarah
Ledniczky, Robert
Sidonio, Robert F. Jr.
Négrier, Claude
Kim, Michelle
Rice, Michelle
Minshall, Matthew
Arcé, Claire
Prince, Steve
Kelleher, Maria
Lee, Sharon
Funding for this research was provided by:
BioMarin Pharmaceutical
Article History
Received: 6 May 2020
Accepted: 23 September 2020
First Online: 28 April 2021
Availability of data and materials
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: Not applicable.
: MKe, SL, and SP are employees of BioMarin Pharmaceutical Inc. All other authors received honoraria/consultancy fees and compensation from BioMarin Pharmaceutical Inc. for their time and expenses incurred in attending interviews, group sessions and/or advisory board held during the implementation of the study; DPH accepted a donation to The Haemophilia Society in lieu of a portion of his fees; MKi donated her fees to the Hemophilia Foundation of Southern California. BB has received advisory board honoraria from Kedrion, Catalyst Biosciences, and Bio Products Laboratory (BPL). CN has received honoraria for consultancy, grant funding, educational activities, or participation in clinical trials from Baxalta/Takeda, Bayer, Biomarin, Catalyst, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, and Spark. RS has received honoraria for consultancy for BioMarin, Genentech/Roche, Octapharma, Sigilon, Tremeau Pharmaceuticals, Catalyst, Uniqure, Spark, Pfizer, Bayer, Takeda, Novo Nordisk, Kedrion and Grifols; and investigator-initiated grant funding from Octapharma, Genentech, Takeda, Kedrion and Grifols.